COMMUNIQUÉS West-GlobeNewswire

Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
16/11/2018
European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness The positive opinion is the result of a 10-year partnership between the Drugs for Neglected Diseases initiative (DND [...]
Sanofi : L'Agence européenne des médicaments recommande l'approbation du fexinidazole, le premier traitement entièrement par voie orale de la maladie du sommeil
16/11/2018
L'Agence européenne des médicaments recommande l'approbation du fexinidazole, le premier traitement entièrement par voie orale de la maladie du sommeil L'avis favorable de l'EMA est l'aboutissement d'une collaboration [...]
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
16/11/2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
16/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long [...]
Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
16/11/2018
– Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining on Treatment Provides Evidence of Prolonged Disease Control – – Favorable Safety Profile at 10 mg and 50 mg, Doses [...]
VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting
16/11/2018
Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel, Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), is reporting results today from its Phase 3 GLOBE study in [...]
AGM Statement
16/11/2018
DXS INTERNATIONAL PLC AGM Statement The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that at [...]
Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting
16/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of [...]
Nouvelle recherche sur l'adénocarcinome canalaire du pancréas publiée dans le Journal of Visualized Experiments
16/11/2018
Ce document décrit des protocoles bien établis pour le développement de modèles d'homogreffes et l'immunoformage des tumeurs orthotopiques d’ACP SAN DIEGO, 16 nov. 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, une société [...]
LIDDS participates at Redeye Life Science Day
16/11/2018
The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology platform. The LIDDS [...]
LIDDS presence at BIO-Europe 2018 to focus on NanoZolid's broad drug formulation capability
16/11/2018
The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology platform. The LIDDS [...]
Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study
16/11/2018
Press Release 16 November 2018 Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study [...]
ReWalk Robotics Announces Pricing of $11.6 Million Public Offering
16/11/2018
YOKNEAM ILIT, ISRAEL and MARLBOROUGH, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ ReWalk ” or the “ Company ”) today announced the pricing of an underwritten public offering of 38,660 [...]
Xbrane Biopharma releases interim report for the third quarter of 2018
16/11/2018
Press release 2018-11-16 Xbrane Biopharma AB's (publ.) ("Xbrane") interim report for the third quarter of 2018 is now available on the Company's website, www.xbrane.com . Financial summary third quarter 2018 Revenue [...]
Rule 2.9 Announcement
16/11/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 16 November 2018 [...]
Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China
16/11/2018
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – LONDON, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) [...]
Shire Announces New HELP Study(TM) Data for Lanadelumab in HAE at 2018 ACAAI Annual Scientific Meeting
16/11/2018
Shire Announces New HELP Study™ Data for Lanadelumab in Hereditary Angioedema (HAE) at 2018 ACAAI Annual Scientific Meeting - Data shows lanadelumab provides significant, clinically meaningful reduction of HAE attacks [...]
DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
16/11/2018
Montrouge, France, November 16, 2018 DBV Technologies Appoints Daniel Tassé as Chief Executive Officer Daniel brings strong track record of building and leading global organizations and delivering transformative [...]
DBV Technologies nomme Daniel Tassé au poste de Directeur Général
16/11/2018
Montrouge, France, le 16 novembre (07h30 CET), 2018 DBV Technologies nomme Daniel Tassé au poste de Directeur Général M. Tassé possède une solide expérience dans la direction de sociétés pharmaceutiques globales et dans [...]

Pages